The short answer
Valerian root may add to drowsiness or impairment with tapentadol. The exact pair’s sedation or breathing-risk increase has not been measured.
What this answer covers
Generic root/rhizome node; Valeriana officinalis evidence applies only when that species/preparation is confirmed.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- tapentadol
The supplement evidence is indirect
Federal guidance advises against combining valerian root with sedatives. A trial’s lack of anxiety or insomnia benefit does not prove absence of sedation.
Tapentadol can impair breathing and alertness
Its labels warn about serious effects with other CNS depressants. This supports caution with sedating supplements, but does not establish a particular supplement’s adverse-event rate.
Preparation and formulation matter
Use the exact supplement label in the review. The generic root name does not confirm the valerian species. Immediate- and extended-release tapentadol are different products; the extended-release tablet must stay intact.
Review before adding a sleep or calming product
Discuss co-use with the prescriber and avoid driving while impaired. Slow breathing or unusual difficulty waking requires emergency help. No short dosing gap has been shown to remove this risk.
Evidence and practical considerations
Side effects & toxicity
Conditional sedation precaution from exact tapentadol label and supplement-specific guidance/effects. No measured pair incidence; preparation and valerian-species limits retained.
- Exact scope
- Generic root/rhizome node; Valeriana officinalis evidence applies only when that species/preparation is confirmed. with Tapentadol RxCUI787390 IN supplied as HCl oral immediate-release or extended-release tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed tapentadol
Opioid and noradrenergic analgesic actions; warnings for CNS-depressant combinations, serotonin syndrome with serotonergic drugs, and seizures in susceptible settings. Mainly glucuronidated; limited CYP metabolism.
How this applies: Exact tapentadol RxCUI 787390 IN, with stated salt/formulation/route bridge.
No herbal-pair risk rate. Immediate and extended release differ. General seizure warning does not establish a St John’s wort-specific seizure interaction.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed tapentadol
Opioid and noradrenergic analgesic actions; warnings for CNS-depressant combinations, serotonin syndrome with serotonergic drugs, and seizures in susceptible settings. Mainly glucuronidated; limited CYP metabolism.
How this applies: Exact tapentadol RxCUI 787390 IN, with stated salt/formulation/route bridge.
No herbal-pair risk rate. Immediate and extended release differ. General seizure warning does not establish a St John’s wort-specific seizure interaction.
Source 3: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for tapentadol only within the stated preparation and endpoint limits.
Not a direct tapentadol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for tapentadol only within the stated preparation and endpoint limits.
Not a direct tapentadol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for tapentadol only within the stated preparation and endpoint limits.
Not a direct tapentadol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact tapentadol article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 4ce6b189fa2474cd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.